Why Arcus Biosciences Stock Vaulted Higher in November

·2 min read
Why Arcus Biosciences Stock Vaulted Higher in November

The biotech's shares ripped higher last month in response to Gilead Sciences (NASDAQ: GILD) exercising its options to develop four of the company's clinical-stage cancer compounds. Specifically, Gilead decided to go forth with the development of two anti-TIGIT antibodies, an A2a/2bR antagonist, as well as a small molecule CD73 inhibitor. Arcus, in turn, received a hefty $725 million upfront payment for the right to develop these four anti-cancer compounds.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting